Assessment of the recoverability of non-
current assets of KGHM International
LTD. and domestic subsidiaries and
investments in the joint venture
Sierra Gorda SCM
As at 31 December 2020, in
the consolidated financial statements,
the Group presents tangible and intangible
assets in the total amount of PLN 25,598
million, which represents 59.9% of the total
assets disclosed in the consolidated
statement of financial position.
During 2020, the Group identified
impairment indicators for the following
subsidiaries:
•
Sociedad Contractual Minera Franke;
•
WPEC S.A.;
•
Pol-Miedź Trans Sp. z o. o.;
•
Uzdrowiska Kłodzkie S.A.;
•
Uzdrowisko Cieplice Sp. z o.o.;
•
Uzdrowisko Świeradów - Czerniawa
Sp. z o.o.;
•
Uzdrowisko Połczyn Sp. z o.o.;
•
Interferie S.A.;
•
Interferie Medical SPA Sp. z o.o.
As a result of impairment tests, the Group:
•
recognized an impairment loss on
the non-current assets of Sociedad
Contractual Minera Franke in
the amount of PLN 45 million,
•
recognized an impairment loss on
the non-current assets of
WPEC S.A. in the amount of PLN
41 million,
•
recognized an impairment loss on
the non-current assets of Pol-Miedź
Trans Sp. z o. o. in the amount of
PLN 21 million,
•
recognized an impairment loss on
the non-current assets of health
resorts (PGU Group) in the total
amount of PLN 94 million.
Disclosures regarding the assessment of
impairment of non-current assets are
presented in part 3 of the consolidated
financial statements.
As at 31 December 2020, the Group
reported the carrying amount of
investments in the Sierra Gorda SCM joint
venture in the amount of PLN 0 (zero)
Our testing procedures included in particular:
•
understanding and assessing the process of
identifying evidence for impairment of assets or
reducing an impairment loss previously
recognized,
•
understanding and assessing the correctness of
the methods used for testing for impairment in
accordance with the relevant financial reporting
standards,
•
understanding and assessing the principles for
determining cash-generating units,
•
a critical assessment of the assumptions and
judgments adopted by the Management Board in
determining the recoverable amount of individual
cash-generating unit subject to impairment tests,
including:
–
the projection period of future cash flows
based on the approved budgets of cash-
generating units for which an impairment
test was carried out and the level of
revenues, operating margin and future
replacement and investment
expenditures assumed in them,
–
the discount rate used (based on
weighted average cost of capital),
–
residual value, including residual growth
rate after the forecast period,
•
checking mathematical correctness and
methodological coherence (using internal
valuation experts) of valuation model based on
discounted cash flows, prepared by the Parent
Company’s Management Board with use of
external experts,
•
checking mathematical correctness and
methodological coherence (using internal
valuation experts) of valuation reports prepared
by independent external experts,
•
assessment of work done by external experts
used by the Parent Company’s Management
Board, including their competence and
independence,
•
assessment of the sensitivity analysis of
the assumptions made by the Parent Company’s
Management Board to the result of the
impairment assessment,
•
assessment of the correctness and
completeness of disclosures regarding
impairment tests in the consolidated financial
statements.